Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Dacogen

Alternative Approaches to Personalized Medicine in Oncology

Laura Towart, Founder & CEO of My Personal Therapeutics, discusses her company’s approach to precision medicine, the barriers patients with cancer face when trying to access personalized treatments, and how...

Impetus Digital

- PMLiVE

BMS links up with Molecular Templates for oncology research collaboration

Deal could be worth up to $1.3bn in milestone payments

- PMLiVE

The heavy toll of COVID-19 on cancer patients

We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Blue Latitude Health

- PMLiVE

Lilly partners with Merus on development of bispecific antibodies for cancer

As part of the deal, Merus could receive a total of up to around $1.6bn for three products

- PMLiVE

GSK’s PD-1 inhibitor dostarlimab shows updated promise in dMMR solid tumours

Investigational PD-1 inhibitor is being studied in mismatch repair-deficient solid tumours

- PMLiVE

bluebird bio to separate oncology and rare diseases units

New oncology company will be led by current bluebird bio CEO Nick Leschly

Delphi Technique Virtual Co-creation: A Customer Story

How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints.

Impetus Digital

- PMLiVE

Kite and Oxford BioTherapeutics sign oncology research pact

Agreement will focus on five novel drug targets across a range of indications

- PMLiVE

Servier to acquire Agios’ oncology business in $1.8bn deal

French pharma will also gain Agios' oncology-associated employees

- PMLiVE

Growing evidence supports the important role of biosimilars in healthcare

New data released at the ASCO Quality Care Symposium continues to underscore the cost-effectiveness of biosimilar treatment options in cancer care

- PMLiVE

GSK pays $85m upfront for Surface Oncology’s lead cancer drug

British pharma company adds preclinical antibody to its pipeline

- PMLiVE

Boehringer spends €1.18bn to acquire NBE-Therapeutics

Company specialises in antibody-drug conjugate development

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links